Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 387,492 shares of the biopharmaceutical company's stock after buying an additional 9,791 shares during the period. Capital Investment Advisors LLC's holdings in Gilead Sciences were worth $35,793,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Bellevue Group AG boosted its stake in Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock worth $3,859,000 after buying an additional 7,093 shares in the last quarter. Quantinno Capital Management LP boosted its stake in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock valued at $6,843,000 after purchasing an additional 48,910 shares during the period. Legal & General Group Plc boosted its stake in shares of Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares during the period. IRON Financial LLC purchased a new stake in shares of Gilead Sciences during the third quarter valued at approximately $830,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Gilead Sciences by 12.9% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company's stock valued at $27,081,000 after purchasing an additional 36,895 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock worth $41,902,086 over the last three months. 0.16% of the stock is currently owned by insiders.
Gilead Sciences Trading Up 0.1 %
Shares of Gilead Sciences stock traded up $0.06 on Monday, reaching $89.94. The company had a trading volume of 6,204,981 shares, compared to its average volume of 6,060,164. The firm has a market cap of $112.09 billion, a price-to-earnings ratio of 999.33, a P/E/G ratio of 2.24 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The firm's 50-day moving average price is $91.94 and its two-hundred day moving average price is $83.39. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the previous year, the business earned $2.29 EPS. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year. As a group, research analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%.
Wall Street Analysts Forecast Growth
GILD has been the subject of a number of recent analyst reports. Daiwa America upgraded Gilead Sciences to a "hold" rating in a report on Monday, November 18th. Mizuho upped their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Robert W. Baird upped their target price on Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Leerink Partnrs upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Finally, The Goldman Sachs Group increased their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.96.
Check Out Our Latest Report on GILD
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
